Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease.
Zimmerman B, Dakin LA, Fortier A, Nanou E, Blasio A, Mann J, Miller H, Fletcher M, Wang T, Nanthakumar S, McCarthy G, Matar C, Matsye P, Wang G, Snyder P, Daniel K, Swamy H, Sullivan K, Bright F, Powers A, Gagnon KJ, Lu F, Paula S, Khare-Pandit S, Henry L, Hamel M, Denis F, Nicolas O, Hariparsad N, Kumar S, Proctor J, Senter T, Furey B, Bunnage ME.
Zimmerman B, et al. Among authors: proctor j.
Nat Commun. 2025 Jan 2;16(1):167. doi: 10.1038/s41467-024-55408-2.
Nat Commun. 2025.
PMID: 39747090
Free article.